Go Deep
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,316 | -6.5 | 3.10 | 0.01 | 2,690.35 |
| Oct 2026 | 19,385 | -6.4 | 3.06 | 0.01 | 2,642.86 |
| Oct 2026 | 19,203 | -6.7 | 3.18 | 0.01 | 2,747.22 |
| Oct 2026 | 19,436 | -6.3 | 3.03 | 0.01 | 2,607.50 |
| Oct 2026 | 19,080 | -6.8 | 3.26 | 0.01 | 2,813.20 |
| Oct 2026 | 18,977 | -7.0 | 3.33 | 0.01 | 2,871.99 |
| Oct 2026 | 19,130 | -6.8 | 3.23 | 0.01 | 2,777.88 |
| Oct 2026 | 19,197 | -6.7 | 3.18 | 0.01 | 2,734.50 |
Celldex Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 22,000.0 | 15,000.0 | 121,000.0 | 0.0 |
| Net Profit | -73,503,000.0 | -78,685,000.0 | -81,317,000.0 | -67,044,000.0 |
| EPS | -0.9 | -1.2 | -1.2 | -1.0 |
Celldex Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 1,545,000.0 | 7,020,000.0 | 6,883,000.0 | 2,357,000.0 | — |
| Net Profit | -258,757,000.0 | -157,863,000.0 | -141,429,000.0 | -112,325,000.0 | — |
| EPS | -3.9 | -2.5 | -2.9 | -2.4 | — |
Celldex Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 582,983,000.0 | 792,340,000.0 | 465,627,000.0 | 352,735,000.0 | — |
| Total Liabilities | 55,818,000.0 | 45,335,000.0 | 36,456,000.0 | 26,531,000.0 | — |
| Total Equity | 527,165,000.0 | 747,005,000.0 | 429,171,000.0 | 326,204,000.0 | — |
Owes vs Owns
Celldex Therapeutics, Inc. owed $0.09 for every $1 it owned in Jun 2026, up from $0.08 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.09× | 0.10× | 0.06× | 0.08× | 0.08× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Celldex Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 89.0%Fixed assets (tangible) 1.3%Intangible assets 4.7%Other assets 4.7%
How it's funded — Dec 2025
Other liabilities 9.0%Shareholders' equity 90.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 518.6 | 725.3 | 423.6 | 305.0 |
| Receivables | 2.0 | 0.7 | 2.6 | 0.3 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 7.8 | 8.2 | 6.6 | 7.7 |
| Intangible assets | 27.2 | 27.2 | 27.2 | 27.2 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 27.4 | 30.9 | 5.6 | 12.5 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 1.5 | 1.6 | 1.4 |
| Long-term debt | 0.8 | 2.4 | 0.9 | 2.6 |
| Payables | 1.2 | 3.3 | 3.5 | 3.3 |
| Other liabilities | 52.3 | 38.3 | 30.4 | 19.2 |
| Shareholders' equity | 527.2 | 747.0 | 429.2 | 326.2 |
| Net tangible assets | 500.0 | 719.8 | 402.0 | 299.0 |
Celldex Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -210,945,000.0 | -157,778,000.0 | -107,291,000.0 | -103,732,000.0 | — |
| Investing Activities | 209,072,000.0 | -290,129,000.0 | -105,782,000.0 | 89,942,000.0 | — |
| Financing Activities | 2,388,000.0 | 441,449,000.0 | 218,458,000.0 | 4,076,000.0 | — |